Format

Send to

Choose Destination

See 1 citation found by title matching your search:

ChemMedChem. 2008 Apr;3(4):619-26. doi: 10.1002/cmdc.200700297.

Total synthesis and initial structure-activity relationships of longicatenamycin A.

Author information

1
Bayer HealthCare, Global Drug Discovery, 42096 Wuppertal, Germany. franz.nussbaum@bayerhealthcare.com

Abstract

Natural products have provided the majority of lead structures for marketed antibacterials. In addition, they are biological guide principles to new therapies. Nevertheless, numerous "old" classes of antibiotics such as the longicatenamycins have never been explored by chemical postevolution. Longicatenamycin A is the first defined longicatenamycin congener that has been totally synthesized and tested in pure form. This venture required the de novo syntheses of the non-proteinogenic amino acids (2S,3R)-beta-hydroxyglutamic acid (HyGlu), 5-chloro-D-tryptophan (D-ClTrp), and (S)-2-amino-6-methylheptanoic acid (hhLeu). In the key step, the sensitive HyGlu building block was coupled as a pentafluorophenyl active ester to the unprotected H-D-ClTrp-Glu-hhLeu-D-Val-D-(Cbz)Orn-OH fragment. This first total synthesis of longicatenamycin A provided new congeners of the natural product (deacetyllongicatenamycin, dechlorolongicatenamycin, and longicatenamycin-A-amide).

PMID:
18246567
DOI:
10.1002/cmdc.200700297
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center